Whalesbook
Orchid Pharma reported that as of March 31, 2026, ₹61.98 crore of its ₹400 crore Qualified Institutional Placement (QIP) funds remained unutilized. The company confirmed that ₹332.56 crore from the QIP has been put to use for various company needs.
Fund Utilization and Project Update
The company's monitoring agency report for the quarter ending March 31, 2026, shows that funds for debt repayment and the Alathur API facility are fully utilized. A significant portion of the capital expenditure focus has been on the Jammu manufacturing facility by Orchid Bio Pharma Limited. However, this project is experiencing considerable delays. Commercial operations at the Jammu site are now anticipated to begin by February 2027, a shift from earlier timelines. Delays in the land acquisition process for the facility are contributing factors. Shareholder approval in September 2025 had previously led to a revised allocation of QIP proceeds, increasing funds for the Jammu facility and debt repayment while reducing the amount for the Alathur API plant.
Impact of Delays
Delays in executing major capital projects like the Jammu manufacturing facility could slow future revenue growth and expansion plans. These setbacks may also affect investor perception of the company's project management capabilities. The financial challenges and debt the company has managed in the past make successful execution of its current growth strategies particularly important for its recovery.
Outlook and Peer Comparison
Orchid Pharma previously raised approximately ₹400 crore through a QIP in late 2022, with funds designated for debt reduction and capital expenditure, including the Jammu facility. In contrast to peers like Divi's Laboratories and Laurus Labs, which typically manage their capital expenditure plans with greater consistency, Orchid Pharma's ongoing delays with the Jammu facility highlight potential project execution challenges.
Investors will be closely monitoring progress on land acquisition for the Jammu site and whether the February 2027 target for commercial operations can be met. Attention will also be focused on how the remaining ₹61.98 crore in QIP funds are utilized and management's approach to overcoming project hurdles.